HeartWare International (NASDAQ: HTWR) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare HeartWare International to related businesses based on the strength of its valuation, dividends, analyst recommendations, institutional ownership, profitability, earnings and risk.
Earnings & Valuation
This table compares HeartWare International and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|HeartWare International Competitors||$1.67 billion||$207.76 million||56.26|
Insider & Institutional Ownership
54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares HeartWare International and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HeartWare International Competitors||-100.14%||-92.44%||-29.75%|
This is a summary of current ratings and recommmendations for HeartWare International and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HeartWare International Competitors||126||738||1041||10||2.49|
As a group, “Medical Devices & Implants” companies have a potential upside of 41.34%. Given HeartWare International’s competitors higher possible upside, analysts plainly believe HeartWare International has less favorable growth aspects than its competitors.
HeartWare International competitors beat HeartWare International on 5 of the 8 factors compared.
About HeartWare International
Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.
Receive News & Ratings for HeartWare International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International and related companies with MarketBeat.com's FREE daily email newsletter.